- Home
- MAZE vs AWP Comparison
MAZE vs AWP Comparison
Compare MAZE & AWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAZE
- AWP
- Stock Information
- Founded
- MAZE 2018
- AWP 2007
- Country
- MAZE United States
- AWP United States
- Employees
- MAZE N/A
- AWP N/A
- Industry
- MAZE
- AWP Trusts Except Educational Religious and Charitable
- Sector
- MAZE
- AWP Finance
- Exchange
- MAZE NYSE
- AWP Nasdaq
- Market Cap
- MAZE 367.0M
- AWP 335.3M
- IPO Year
- MAZE 2025
- AWP N/A
- Fundamental
- Price
- MAZE $16.93
- AWP $3.90
- Analyst Decision
- MAZE Strong Buy
- AWP
- Analyst Count
- MAZE 4
- AWP 0
- Target Price
- MAZE $23.50
- AWP N/A
- AVG Volume (30 Days)
- MAZE 129.8K
- AWP 331.5K
- Earning Date
- MAZE 08-14-2025
- AWP 01-01-0001
- Dividend Yield
- MAZE N/A
- AWP 12.48%
- EPS Growth
- MAZE N/A
- AWP N/A
- EPS
- MAZE 0.34
- AWP N/A
- Revenue
- MAZE $167,500,000.00
- AWP N/A
- Revenue This Year
- MAZE N/A
- AWP N/A
- Revenue Next Year
- MAZE N/A
- AWP N/A
- P/E Ratio
- MAZE $53.00
- AWP N/A
- Revenue Growth
- MAZE N/A
- AWP N/A
- 52 Week Low
- MAZE $6.71
- AWP $3.06
- 52 Week High
- MAZE $18.50
- AWP $4.20
- Technical
- Relative Strength Index (RSI)
- MAZE N/A
- AWP 40.81
- Support Level
- MAZE N/A
- AWP $3.80
- Resistance Level
- MAZE N/A
- AWP $3.87
- Average True Range (ATR)
- MAZE 0.00
- AWP 0.05
- MACD
- MAZE 0.00
- AWP -0.01
- Stochastic Oscillator
- MAZE 0.00
- AWP 20.59
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.